Steatotic Liver Disease
Also known as: ALD, Alcohol-associated liver disease, Alcoholic fatty liver disease, Fatty Liver Disease, MASLD
Methodology & AI Transparency ⓘ
Steatotic Liver Disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is steatotic liver disease? Your liver is the largest organ inside your body.
- 2 Real-world patient consensus: Clinical coding for Steatotic Liver Disease uses ICD-10 K81.6 across Liver & Hepatology specialty care.
- 3 Typical cash cost range: Workup highlights for Steatotic Liver Disease (K81.6): hepatotoxic medication audit [Steatotic Liver Disease K81.6].
- 4 Top reported side effects / signs: Longitudinal Steatotic Liver Disease monitoring tracks Fasting Lipase & in Steatotic Liver Disease (K81.6: Triglycerides) toward Normal enzymatic baseline (K81.6).
Ask our AI Specialists anything about Steatotic Liver Disease
What Is Steatotic Liver Disease?
What is steatotic liver disease? Your liver is the largest organ inside your body. It helps you digest food, store energy, and remove harmful substances (toxins). Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. It's typical to have some fat in your liver cells, but too much can be a problem. There are two main types of steatotic liver disease: Metabolic dysfunction-associated steatotic liver disease (MASLD) Alcohol-associated liver disease (ALD) What is metabolic dysfunction-associated steatotic liver disease (MASLD)? MASLD is a type of steatotic liver disease that is not caused by heavy alcohol use.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Steatotic Liver Disease (K81.6) center on cholestatic bile-duct obstruction [Steatotic Liver Disease K81.6]. Cross-referenced with NIH MeSH (Fatty Liver, Non-alcoholic Fatty Liver Disease), targeted liver & hepatology interventions aim to normalize Fasting Lipase & in Steatotic Liver Disease (K81.6: Triglycerides).
Common Symptoms & Clinical Signs
- • Metabolic dysfunction-associated steatotic liver disease (MASLD)
- • Alcohol-associated liver disease (ALD)
- • Presentation of Steatotic Liver Disease (K81.6): epigastric pain, steatorrhea [Steatotic Liver Disease K81.6]
- • Secondary Steatotic Liver Disease clinical sign: asymptomatic elevation of in Steatotic Liver Disease (K81.6: liver transaminases)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Steatotic Liver Disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K81.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Liver, Gallbladder & Pancreatic Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipase & in Steatotic Liver Disease (K81.6: Triglycerides) | Normal enzymatic baseline (K81.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT, AST, Alkaline in Steatotic Liver Disease (K81.6: Phosphatase & GGT) | ALT < 25 U/L (men) / < 19 U/L (women) (K81.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: FIB-4 Hepatic Fibrosis in Steatotic Liver Disease (K81.6: Index) | < 1.30 (K81.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Steatotic Liver Disease
Treatment selection for Steatotic Liver Disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Steatotic Liver Disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on [Comment] Non-invasive tests in MASH: clinical practice versus Non-invasive tests (NITs) are central to clinical decision making in metabolic dysfunction-associated steatotic liver disease, including risk stratification, treatment decisions, referral pathways, and recruitment into clinical trials.1 As pharmacological trea The Lancet • 2026-10-31 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 90/100 | PMID LANCET-3803036223 ↗ |
Steatotic Liver Disease Patient Community & “People Like Me” Threads
Filter Steatotic Liver Disease community threads and patient logs by age, biological sex, dosage, and treatment duration.